PKM and pulmonary fibrosis: Thus, experiments with both liver and lung fibrosis mouse models suggest that PKM2 activator reverses fibrosis by facilitating glycolysis flow, which leads to a decreased accumulation of glycolytic intermediates that are channeled to glycine synthesis.